A Study of Dasatinib Management Among CP-CML (Chronic Phase, Chronic Myeloid Leukemia) Participants Initiating Dasatinib in a Real Life Setting

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Chronic Myeloid Leukemia

Treatments: Other: Non-Interventional

Study type: Observational

Funder types: Industry

Identifiers

NCT04089839

CA180-616

Details and patient eligibility

About

This is a prospective, non-interventional study conducted in CP-CML patients receiving dasatinib who are enrolled by a sample of hematologists in France.

Enrollment: 177 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients aged greater than or equal to 18 years
• Patients diagnosed with CP-CML
• Patients who started dasatinib within the last month before inclusion, or on the day of inclusion or within the month after inclusion

Exclusion criteria

• Patients participating in an ongoing interventional trial
• Patients diagnosed with AP-CML (accelerated phase) or BP-CML (blast phase)

Trial design

177 participants in 1 patient group

CP-CML participants initiating dasatinib

Treatment:

Other: Non-Interventional